REQUEST PRICE

Fields with * are required
Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Urotensin Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Agonist-induced Serine360/Serine361 phosphorylation of the Urotensin Receptor
pS360/pS361-UT (phospho-Urotensin Receptor...
Serine360/Serine361 (S360/S361) is major phosphorylation site of the Urotensin Receptor (UT). The pS360/pS361-UT antibody detects phosphorylation in response to agonists. S360/S361 phosphorylation is likely to be involved in efficient...
$ 350.00
NEW
Validation of the Urotensin Receptor in transfected HEK293 cells
UT (non-phospho), Urotensin Receptor Antibody
The UT receptor antibody is directed against the distal end of the carboxyl-terminal tail of human Urotensin Receptor. It can be used to detect total UT receptors in Western blots independent of phosphorylation. The UT antibody can also...
$ 250.00

UT

The urotensin-II receptor (UT) is activated by the endogenous dodecapeptide urotensin-II (U-II), originally isolated from the urophysis, the endocrine organ of the caudal neurosecretory system of teleost fish. Human urotensin-II, an 11-amino-acid peptide, retains the cyclohexapeptide sequence that is thought to be important in ligand binding. A second endogenous ligand for the UT has been discovered in rat. This is the urotensin II-related peptide, an octapeptide that is derived from a different gene, but shares the C-terminal sequence (CFWKYCV) common to U-II from other species. The UT receptor exhibits relatively high sequence identity with somatostatin, opioid and galanin receptors.U-II isopeptides are potent and sustained mammalian vasoconstrictors in vitro. This phenomenon is observed primarily in arterial vasculature, consistent with the expression of UT in cardiac and arterial, but not venous, blood vessels and smooth muscle cell lines. Vasoconstriction is resistant to block of adrenergic or cholinergic systems, 5-HT or histamine receptor antagonism. Since responses are reported to be phospholipase-sensitive, such an effect is likely secondary to phosphoinositide metabolism. This is consistent with observations made using recombinant receptors where receptor activation is coupled to Ca2+ and arachidonate hydrolysis in cultured cells. UT receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine360/serine361 (pS360/pS361-UT). This nomenclature refers to the human UT receptor. This phosphorylation motif corresponds to pS363/pS364-UT in mice. For more information on UT receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Vaudry H, Leprince J, Chatenet D, Fournier A, Lambert DG, Le Mével JC, Ohlstein EH, Schwertani A, Tostivint H, Vaudry D. International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function. Pharmacol Rev. 2015;67(1):214-58. doi: 10.1124/pr.114.009480. PMID: 25535277.

The urotensin-II receptor (UT) is activated by the endogenous dodecapeptide urotensin-II (U-II), originally isolated from the urophysis, the endocrine organ of the caudal neurosecretory... read more »
Close window
Urotensin Receptor Antibodies

UT

The urotensin-II receptor (UT) is activated by the endogenous dodecapeptide urotensin-II (U-II), originally isolated from the urophysis, the endocrine organ of the caudal neurosecretory system of teleost fish. Human urotensin-II, an 11-amino-acid peptide, retains the cyclohexapeptide sequence that is thought to be important in ligand binding. A second endogenous ligand for the UT has been discovered in rat. This is the urotensin II-related peptide, an octapeptide that is derived from a different gene, but shares the C-terminal sequence (CFWKYCV) common to U-II from other species. The UT receptor exhibits relatively high sequence identity with somatostatin, opioid and galanin receptors.U-II isopeptides are potent and sustained mammalian vasoconstrictors in vitro. This phenomenon is observed primarily in arterial vasculature, consistent with the expression of UT in cardiac and arterial, but not venous, blood vessels and smooth muscle cell lines. Vasoconstriction is resistant to block of adrenergic or cholinergic systems, 5-HT or histamine receptor antagonism. Since responses are reported to be phospholipase-sensitive, such an effect is likely secondary to phosphoinositide metabolism. This is consistent with observations made using recombinant receptors where receptor activation is coupled to Ca2+ and arachidonate hydrolysis in cultured cells. UT receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine360/serine361 (pS360/pS361-UT). This nomenclature refers to the human UT receptor. This phosphorylation motif corresponds to pS363/pS364-UT in mice. For more information on UT receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Vaudry H, Leprince J, Chatenet D, Fournier A, Lambert DG, Le Mével JC, Ohlstein EH, Schwertani A, Tostivint H, Vaudry D. International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function. Pharmacol Rev. 2015;67(1):214-58. doi: 10.1124/pr.114.009480. PMID: 25535277.

Recently viewed